Grenoble, France, 5th April, 2022
CYTOO and Astellas Gene Therapies (AGT) entered into a research collaboration in 2020 to select AGT’s AAV gene therapy clinical candidate to treat Duchenne Muscular Dystrophy (DMD). Today, AGT will present the results of this collaboration at the 2nd Gene Therapy for Muscular Disorders Summit in Boston.
DMD is a rare and life-threatening genetic disorder that affects children–approximately 1 in 3,500 to 5,000 boys–and families. It is caused by mutations in the dystrophin gene that results in progressive muscle degeneration and weakness. By the early...
You are here
News
28 February 2020
Grenoble, France and Research Triangle Park, NC, 28 February, 2020
CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research collaboration aimed at selecting a gene therapy candidate for a rare muscle disorder with Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage, fully integrated adeno-associated virus (AAV) gene therapy company. Under the terms of the agreement, AskBio and CYTOO will work together to develop an AAV-based screening platform derived from patient cells. The goal of the collaboration is to screen and select a...
23 October 2019
Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology
Intend to identify EMM compositions that promote skeletal muscle growth and function across multiple disease contexts
Cambridge, Mass. – October 23, 2019 – Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced a collaboration with CYTOO aimed at informing the development of new AXA Candidates by leveraging CYTOO’s MyoScreenTM...
06 September 2018
Grenoble, France and NEW YORK, 6 September, 2018
CYTOO and Pfizer Inc. (NYSE: PFE) announced a research collaboration to modify CYTOO’s existing MyoScreenTM platform to enable its potential use as a Duchenne muscular dystrophy (DMD) target discovery platform.
DMD is a rare and life-threatening genetic disorder that affects children–approximately 1 in 3,500 to 5,000 boys–and families. It is caused by mutations in the dystrophin gene that results in progressive muscle degeneration and weakness. By the early teens, most individuals with DMD have lost the ability to walk...
16 October 2017
Artificial visible light is everywhere in our modern life. Our mode of social communication confronts us with screens of all kinds and their use is on the rise.
Curious to discover the potential consequences of such an environment on skin health, GATTEFOSSÉ initiated a two-year investigation with CYTOO to determine the direct effects of screen exposure on the skin.
Unique equipment was designed by GATTEFOSSÉ to accurately recreate the characteristic light emitted by screens of electronic devices (smartphones, tablets, PC).
By using micropatterning technology, a method to guide cell shape...
25 January 2017
CYTOO’s JALA cover page featured paper “Fully Automated One-Step Production of Functional 3D Tumor Spheroids for High-Content Screening“ has been elected among the 2017 SLAS Technology Ten award
13 January 2017
Polarity Reversal by Centrosome Repositioning Primes Cell Scattering during Epithelial-to-Mesenchymal Transition
22 January 2016
January 21, 2016, Grenoble, France – BASF and the French biotechnology company CYTOO join forces. The goal of the partnership is to develop and test active ingredients that contribute to increase skin firmness in skin care applications.
Recent research results indicate that there are some ingredients that can stimulate the contractility of human fibroblasts (connective tissue cells) and thus improve skin appearance and firmness. To investigate more deeply these cell features, CYTOO developed FibroScreen™. This unique platform is based upon a micro-patterning technology that allows the...
28 October 2015
October 28th, 2015, Grenoble, France- CYTOO announces today that Daiichi Sankyo Company Limited, a Japanese pharmaceutical manufacturer with global presence, has selected CYTOO in vitro muscle platform MyoScreen™ to develop a novel cell-based assay and screen drug candidates on a key mechanism involved in several muscular diseases.
MyoScreen™ is a high throughput and high content screening platform that enables the identification and characterization of new compounds that affect muscle hypertrophy, contractility, metabolism and muscular diseases. The system thus meets the broad...
16 July 2015
Grenoble, France, 16th July 2015 - CYTOO, a biotechnology company specialized in the development of physiologically-relevant high content cellular assays, announces today the commercial launch of MyoScreenФ™, a new screening platform for the identification of novel active molecules that can be used to treat musculoskeletal and neuromuscular disorders.
CYTOO, the first in the world to model a human muscle in vitro
By combining the technology of adhesive micropatterns with muscle cells isolated from human donors, CYTOO has created the first in vitro model of mature human muscle....
Pages
About us
Archive
- 2022
- April (1)
- 2020
- February (1)
- 2019
- October (1)
- 2018
- September (1)
- 2017
- January (2)
- October (1)
- 2016
- January (1)
- 2015
- July (1)
- October (1)
- 2014
- December (1)
- 2010
- June (1)
- November (1)
- 2008
- June (1)
- July (1)
- December (1)
Like us on Facebook
Find us on Twitter
Connect via Linkedin
Watch us on YouTube
Join us on SlideShare
Discover us on Scoop.it!
RSS